Systemic lupus erythematosus (SLE) is a chronic, heterogeneous autoimmune disease characterized by multisystem involvement and substantial morbidity. Although survival has improved over recent decades, disease burden remains considerable due to cumulative organ damage, comorbidities, and treatment-related toxicity, particularly from long-term glucocorticoid use. Advances in the understanding of SLE immunopathogenesis have led to the development of targeted therapies. Currently approved agents include belimumab and anifrolumab, while obinutuzumab has been approved for lupus nephritis and has also demonstrated significant efficacy in phase III trials in SLE. Several additional agents are in late-stage clinical development, including litifilimab (targeting plasmacytoid dendritic cells), telitacicept and ianalumab (BAFF/APRIL and B-cell modulation), dapirolizumab pegol (CD40L blockade), deucravacitinib and upadacitinib (TYK2/JAK inhibition), and cenerimod (S1P11 modulation). This narrative review summarizes current phase III evidence and emerging therapeutic strategies, highlighting the ongoing transition toward precision medicine and individualized treatment approaches in SLE.
Assessing quality of life in patients with axial spondyloarthritis (axSpA) is essential for capturing the full burden of the disease beyond clinical and im
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical manifestations. Timely diagnosis and accurate assessment of disease activity are essential for determining optimal therapeutic strategies for each patient. Over recent decades, the prognosis for SLE patients has significantly improved. However, even with proper treatment and remission, quality of life (QoL) remains substantially impaired. This underscores the importance of evaluating health-related quality of life (HRQoL) as part of a comprehensive approach to managing SLE patients. A holistic understanding of a patient`s overall condition involves not only physical health but also psychological and social well-being. In recent years, numerous QoL questionnaires have been increasingly utilized in rheumatological practice. Generic questionnaires, such as the Short Form-36 (SF-36), facilitate comparisons across different diseases but may lack sensitivity to the specific clinical symptoms of SLE. Conversely, lupus-specific questionnaires, including LupusQoL, SLEQOL, LupusPRO, and L-QoL, offer more precise insights by capturing multiple aspects of the disease from the patient`s perspective. Current guidelines emphasize the need to integrate HRQoL assessments into routine clinical practice and research. The literature review highlights the growing role of lupus-specific questionnaires in clinical trials and raises the critical question of their effectiveness and applicability in daily practice to improve medical care.
22 February 2026 in International Journal of Rheumatic Diseases